Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Rhythm Biosciences Ltd. ( (AU:RHY) ).
Rhythm Biosciences Limited has applied for quotation of 1,951,494 new fully paid ordinary shares on the Australian Securities Exchange, to be issued on 2 April 2026. The additional securities arise from the exercise or conversion of existing options or other convertible instruments, slightly expanding the company’s share base and providing incremental capital or equity flexibility for ongoing operations and growth initiatives.
The most recent analyst rating on (AU:RHY) stock is a Hold with a A$0.18 price target. To see the full list of analyst forecasts on Rhythm Biosciences Ltd. stock, see the AU:RHY Stock Forecast page.
More about Rhythm Biosciences Ltd.
Rhythm Biosciences Limited is an Australian-listed biotechnology company trading on the ASX under the code RHY. The company operates in the life sciences sector, focusing on the development and commercialisation of diagnostic technologies, with its securities listed and traded on the Australian Securities Exchange.
Average Trading Volume: 955,296
Technical Sentiment Signal: Buy
Current Market Cap: A$61.79M
Find detailed analytics on RHY stock on TipRanks’ Stock Analysis page.